ID
34739
Descripción
Study ID: 104951 Clinical Study ID: 104951 Study Title: A Phase III, double-blind, randomized, controlled study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 vaccine administered intramuscularly according to a 0_ 1_ 6 month schedule in healthy female subjects aged 10 - 14 years. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00290277 https://clinicaltrials.gov/ct2/show/NCT00290277 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: HPV-16/18 L1/AS04 Vaccine Trade Name: N/A Study Indication: Infections, Papillomavirus This form contains information about Contraindications to subsequent vaccination and should be checked at visit 1(Month 0, pre-vacc), 2(Month 1) and 3(Month 6).
Link
https://clinicaltrials.gov/ct2/show/NCT00290277
Palabras clave
Versiones (1)
- 25/1/19 25/1/19 -
Titular de derechos de autor
GlaxoSmithKline
Subido en
25 de enero de 2019
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Evaluation of immunogenicity and safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine in healthy females NCT00290277
Contraindications to subsequent vaccination
- StudyEvent: ODM
Descripción
Absolute contraindications to further administration of vaccine
Alias
- UMLS CUI-1
- C2368628
- UMLS CUI-2
- C1301624
- UMLS CUI-3
- C0205344
Descripción
Clinically significant decreased liver or renal function
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0232807
- UMLS CUI [1,2]
- C2985739
- UMLS CUI [1,3]
- C2368628
- UMLS CUI [1,4]
- C0683610
- UMLS CUI [2,1]
- C0232744
- UMLS CUI [2,2]
- C2985739
- UMLS CUI [2,3]
- C2368628
- UMLS CUI [2,4]
- C0683610
Descripción
Immunodeficient condition
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0021051
- UMLS CUI [1,2]
- C0750484
- UMLS CUI [1,3]
- C0262926
- UMLS CUI [2,1]
- C0021051
- UMLS CUI [2,2]
- C0332147
- UMLS CUI [2,3]
- C0262926
- UMLS CUI [3,1]
- C0021051
- UMLS CUI [3,2]
- C0750484
- UMLS CUI [3,3]
- C0031809
- UMLS CUI [4,1]
- C0021051
- UMLS CUI [4,2]
- C0332147
- UMLS CUI [4,3]
- C0031809
Descripción
Pregnancy
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0032961
Descripción
Hypersensitivity reaction following vaccine administration
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0020517
- UMLS CUI [1,2]
- C2368628
- UMLS CUI [2,1]
- C0042109
- UMLS CUI [2,2]
- C2368628
Descripción
Anaphylactic reaction following the administration of study/ control vaccine(s).
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0002792
- UMLS CUI [1,2]
- C2368628
Descripción
A serious adverse event (SAE) is any untoward medical occurrence that: results in death, is life threatening, results in persistent or significant disability / incapacity, requires in-patient hospitalization, prolongation of existing hospitalization or is a congenital anomaly / birth defect in the offspring of a study subject. In addition, important medical events that may jeopardize the subject or may require intervention to prevent one of the other outcomes listed above should be considered serious. (Examples of such events are invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization.) For each serious adverse event the investigator becomes aware of, please fill in a Serious Adverse Event (SAE) report.
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C1519255
- UMLS CUI [1,2]
- C1875384
Descripción
Other significant reactions which in the opinion of the investigator (or designate) preclude further administration of the study/ control vaccine
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0683610
- UMLS CUI [1,2]
- C2368628
- UMLS CUI [1,3]
- C0443286
- UMLS CUI [1,4]
- C2985739
- UMLS CUI [2]
- C0278140
- UMLS CUI [3,1]
- C0038999
- UMLS CUI [3,2]
- C0205082
- UMLS CUI [4,1]
- C0026597
- UMLS CUI [4,2]
- C0449295
- UMLS CUI [4,3]
- C0205082
- UMLS CUI [5]
- C0476474
- UMLS CUI [6,1]
- C0018681
- UMLS CUI [6,2]
- C0205082
- UMLS CUI [7,1]
- C1710276
- UMLS CUI [7,2]
- C0205394
- UMLS CUI [8,1]
- C0853813
- UMLS CUI [8,2]
- C0205394
Descripción
Contraindications to administration of vaccine at current time
Alias
- UMLS CUI-1
- C2368628
- UMLS CUI-2
- C1301624
- UMLS CUI-3
- C0521116
Descripción
Acute disease is defined as the presence of a moderate or severe illness with or without fever. Enrolment will be deferred until condition is resolved. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. oral temperature < 37.5 °C (99.5 °F)/axillary temperature < 37.5 °C (99.5 °F).
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0001314
- UMLS CUI [1,2]
- C0150312
- UMLS CUI [1,3]
- C2368628
Descripción
Oral/axillary temperature ≥37.5 °C (99.5 °F) at the time of vaccination
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0039476
- UMLS CUI [1,2]
- C0442027
- UMLS CUI [1,3]
- C0042196
- UMLS CUI [1,4]
- C0040223
- UMLS CUI [2,1]
- C1531924
- UMLS CUI [2,2]
- C0042196
- UMLS CUI [2,3]
- C0040223
Similar models
Contraindications to subsequent vaccination
- StudyEvent: ODM
C1301624 (UMLS CUI-2)
C0205344 (UMLS CUI-3)
C2985739 (UMLS CUI [1,2])
C2368628 (UMLS CUI [1,3])
C0683610 (UMLS CUI [1,4])
C0232744 (UMLS CUI [2,1])
C2985739 (UMLS CUI [2,2])
C2368628 (UMLS CUI [2,3])
C0683610 (UMLS CUI [2,4])
C0750484 (UMLS CUI [1,2])
C0262926 (UMLS CUI [1,3])
C0021051 (UMLS CUI [2,1])
C0332147 (UMLS CUI [2,2])
C0262926 (UMLS CUI [2,3])
C0021051 (UMLS CUI [3,1])
C0750484 (UMLS CUI [3,2])
C0031809 (UMLS CUI [3,3])
C0021051 (UMLS CUI [4,1])
C0332147 (UMLS CUI [4,2])
C0031809 (UMLS CUI [4,3])
C2368628 (UMLS CUI [1,2])
C0042109 (UMLS CUI [2,1])
C2368628 (UMLS CUI [2,2])
C2368628 (UMLS CUI [1,2])
C1875384 (UMLS CUI [1,2])
C2368628 (UMLS CUI [1,2])
C0443286 (UMLS CUI [1,3])
C2985739 (UMLS CUI [1,4])
C0278140 (UMLS CUI [2])
C0038999 (UMLS CUI [3,1])
C0205082 (UMLS CUI [3,2])
C0026597 (UMLS CUI [4,1])
C0449295 (UMLS CUI [4,2])
C0205082 (UMLS CUI [4,3])
C0476474 (UMLS CUI [5])
C0018681 (UMLS CUI [6,1])
C0205082 (UMLS CUI [6,2])
C1710276 (UMLS CUI [7,1])
C0205394 (UMLS CUI [7,2])
C0853813 (UMLS CUI [8,1])
C0205394 (UMLS CUI [8,2])
C1301624 (UMLS CUI-2)
C0521116 (UMLS CUI-3)
C0150312 (UMLS CUI [1,2])
C2368628 (UMLS CUI [1,3])
C0442027 (UMLS CUI [1,2])
C0042196 (UMLS CUI [1,3])
C0040223 (UMLS CUI [1,4])
C1531924 (UMLS CUI [2,1])
C0042196 (UMLS CUI [2,2])
C0040223 (UMLS CUI [2,3])